279 related articles for article (PubMed ID: 12385004)
1. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
[TBL] [Abstract][Full Text] [Related]
4. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
[TBL] [Abstract][Full Text] [Related]
7. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
9. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
[TBL] [Abstract][Full Text] [Related]
10. Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.
Amoh Y; Li L; Tsuji K; Moossa AR; Katsuoka K; Hoffman RM; Bouvet M
J Surg Res; 2006 May; 132(2):164-9. PubMed ID: 16500746
[TBL] [Abstract][Full Text] [Related]
11. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
12. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
Bruns CJ; Solorzano CC; Harbison MT; Ozawa S; Tsan R; Fan D; Abbruzzese J; Traxler P; Buchdunger E; Radinsky R; Fidler IJ
Cancer Res; 2000 Jun; 60(11):2926-35. PubMed ID: 10850439
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.
Bruns CJ; Koehl GE; Guba M; Yezhelyev M; Steinbauer M; Seeliger H; Schwend A; Hoehn A; Jauch KW; Geissler EK
Clin Cancer Res; 2004 Mar; 10(6):2109-19. PubMed ID: 15041732
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Kedar D; Baker CH; Killion JJ; Dinney CP; Fidler IJ
Clin Cancer Res; 2002 Nov; 8(11):3592-600. PubMed ID: 12429651
[TBL] [Abstract][Full Text] [Related]
16. Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
Solorzano CC; Hwang R; Baker CH; Bucana CD; Pisters PW; Evans DB; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 May; 9(5):1858-67. PubMed ID: 12738744
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
Mita Y; Ajiki T; Kamigaki T; Okazaki T; Hori H; Horiuchi H; Hirata K; Fujita T; Fujimori T; Kuroda Y
Ann Surg Oncol; 2007 Apr; 14(4):1374-80. PubMed ID: 17235714
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites.
Kuwahara K; Sasaki T; Kobayashi K; Noma B; Serikawa M; Iiboshi T; Miyata H; Kuwada Y; Murakami M; Yamasaki S; Kariya K; Morinaka K; Chayama K
Oncol Rep; 2004 Jan; 11(1):73-80. PubMed ID: 14654905
[TBL] [Abstract][Full Text] [Related]
20. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
